The BC Cancer Agency has designed a randomized controlled trial for patients with metastatic breast cancer. The trial seeks to uncover the effects of adding NKTR-102 once every 3 weeks to a patient's existing intravenous chemotherapy regimen.
More information on this trial can be found
here.
No comments:
Post a Comment